A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors

RECRUITING

Scientia Clinical Research Ltd, Randwick

RECRUITING

Macquarie University, Sydney

RECRUITING

Peninsula and south eastern haematology and oncology group, Frankston

NOT_YET_RECRUITING

Mater Cancer Care Centre, Mater Misericordiae Limited, South Brisbane

RECRUITING

Princess Alexandra Hospital, Woolloongabba

RECRUITING

Gold Coast Private Hospital, Southport

RECRUITING

CHA Bundang Medical Center, CHA University, Seongnam-si

RECRUITING

Cayuga Medical Center, Ithaca

RECRUITING

Gachon University - Gil Medical Center, Incheon

RECRUITING

Medical University of South Carolina (MUSC) - Hollings CC, Charleston

RECRUITING

Advent Health Research Institute, Celebration

RECRUITING

Sarah Cannon Research Institue Oncology, Nashville

RECRUITING

Karmanos Cancer Institute, Detroit

RECRUITING

Washington University - Siteman Cancer Center, St Louis

RECRUITING

START - South Texas Accelerated Research Therapeutics, San Antonio

RECRUITING

Sarah Cannon Research Institute Health One, Denver

RECRUITING

START Mountain Region, West Valley City

RECRUITING

University California Irvine, Irvine

RECRUITING

University of California San Francisco (UCSF), San Francisco

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

RECRUITING

Zhejiang Cancer Hospital, Hangzhou

RECRUITING

Chongqing University Cancer Hospital, Chongqing

RECRUITING

Smilow Cancer Hospital at Yale New Haven, New Haven

RECRUITING

Severance Hospital, Yonsei University Health System, Seoul